Compare Kraft Heinz Co (KHC) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs McKesson Corporation — how do they compare? Kraft Heinz Co trades at $22.27 (market cap $26.66B), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 4.1× Kraft Heinz Co's market cap, and Kraft Heinz Co pays the higher dividend (7.12%). Which is the better fit depends on your goals — on Pluang, investors hold Kraft Heinz Co for 129 Days and McKesson Corporation for 74 Days on average.
| KHC | MCK | |
|---|---|---|
Market Cap | $26.66B | $108.46B |
Volume | 31,300,109 | 712,607 |
Sector | Consumer Staples | Health |
52-Week High | $27.62 | $995.69 |
52-Week Low | $21.21 | $725.17 |
Typical Hold Time | 129 Days | 74 Days |
Enterprise Value | $42.98B | $115.00B |
Dividend Yield | 7.12% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $22.48, up 2.27% today, but remains in a bearish technical trend. The company reported a net loss of $5.85 billion in 2025 due to a significant impairment charge, though recent quarters have beaten EPS estimates. Operating cash flow remains strong at $4.46 billion, supporting a $0.40 dividend. News highlights focus on brand revitalization efforts, such as new Philadelphia cream cheese flavors, as part of a broader turnaround strategy.
The outlook is mixed: valuation metrics like P/B of 0.74 suggest potential undervaluation, but persistent net losses and high debt pose risks. Analyst sentiment is cautious with a consensus price target of $24.50. The stock's near-term direction hinges on successful execution of cost management and volume recovery initiatives amid competitive pressures.
McKesson (MCK) trades at $930.25, up 2.19% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue growth is robust, reaching $359.05B in 2025, though net margins are thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing long-term visibility.
The outlook is positive, driven by operational strength and strategic partnerships, but investors face risks from margin pressure and drug pricing uncertainty. With 81% of analysts rating it Buy and a consensus target of $956.43, the stock offers upside, though high RSI levels suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
